Welcome to our dedicated page for Phibro Animal Health news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (Nasdaq: PAHC) reported fourth-quarter and fiscal year 2024 results, showing mixed performance. Q4 Highlights: Net sales rose 7% to $273.2M; net income dropped $10.7M to $0.8M; diluted EPS fell by $0.26 to $0.02. Adjusted EBITDA increased 3% to $33.4M; adjusted net income rose 10% to $16.7M. Fiscal Year 2024 Highlights: Net sales grew 4% to $1.02B; net income decreased by $30.2M to $2.4M; diluted EPS dropped $0.75 to $0.06. Adjusted EBITDA fell 1% to $111.2M; adjusted net income dipped by 1% to $48.4M. Guidance for FY 2025: Net sales projected at $1.040B to $1.090B; adjusted EBITDA between $118M-$126M. CEO Jack Bendheim highlighted strength in Q4 performance and expects continued growth, especially in Animal Health.
Phibro Animal Health (Nasdaq: PAHC) has announced it will release its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after market close. The company will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time to discuss the results. Interested parties can access the webcast and presentation slides at https://investors.pahc.com. The call will also be available via phone, with separate numbers for U.S./Canada and international callers. A replay of the webcast will be available approximately two hours after the event concludes.
Phibro Animal Health (Nasdaq: PAHC) has announced a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. The dividend is set to be paid on September 25, 2024, to stockholders of record as of the close of business on September 4, 2024. This decision was made by the company's Board of Directors, demonstrating their commitment to returning value to shareholders. The consistent dividend payout suggests financial stability and confidence in the company's future performance.
Phibro Animal Health (Nasdaq: PAHC) has released its third annual Environmental, Social, and Governance (ESG) Report, highlighting 2023 achievements. The report emphasizes Phibro's commitment to enhancing animal health and nutrition to promote sustainability. Significant efforts include disease prevention, waste reduction, and resource conservation, which contribute to a safer, more affordable food supply. These initiatives align with the UN's 2030 Sustainable Development Goals (SDGs). The report underscores the importance of the One Health approach, emphasizing interconnections among the health of people, animals, and the planet. Phibro’s work in 2023 focused on reducing greenhouse gas emissions, enhancing food production efficiency, and supporting farmers' economic stability. This contributes to mitigating climate change and promoting food security. The company aims to continue driving sustainability and ethical growth, ensuring positive global contributions.
Phibro Animal Health (Nasdaq: PAHC) announced its participation in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference.
Key executives including CFO Glenn David, COO Larry Miller, and EVP Corporate Strategy Daniel Bendheim will present to financial analysts and investors on May 29, 2024, at 10:20 AM ET, at the St. Regis New York.
The live audio presentation will be accessible on the Phibro Animal Health Investor Relations Website, with a replay available for later viewing.
Phibro Animal Health reported strong financial results for the third quarter, with net sales increasing by 7% and adjusted EBITDA up by 9%. The company affirmed its fiscal year 2024 guidance, including net sales of $980 million to $1.020 billion and adjusted diluted EPS of $1.04 to $1.16. Phibro also updated its guidance for net income and diluted EPS due to recent developments.
Phibro Animal Health (PAHC) announced a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock, payable on June 26, 2024. The dividend will be distributed to stockholders of record as of June 5, 2024.
Summary not available.
Summary not available.
Summary not available.